Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

ABArwa BohraSDSurendra DasariMBMoritz Binder

Discussion

Loading...

Member takes

Overview

RNA-seq analysis identifies high-risk immunophenotypes in multiple myeloma, indicating tailored therapies may be necessary.

Key Points

  • Gene expression profiling revealed distinct immunophenotypes in newly diagnosed multiple myeloma patients, impacting survival outcomes.
  • Finding 27.7% of patients in the classical cluster showed high-risk disease per the International Myeloma Society criteria.
  • Pathway analysis was performed using RNA-seq data to identify prognostic biomarkers in multiple myeloma.
  • The study calls for tailored therapies for high-risk patients based on identified immunophenotypes to improve outcomes.

Cite This Study

Bohra et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d522https://doi.org/10.1182/blood-2025-7477
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  2. 2Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  3. 3Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis2025
  4. 4Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  5. 5Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights2025